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Abstract: The gold(I)-catalyzed reaction of N-Boc-protected 6-
alkynyl-3,4-dihydro-2H-pyridines, which affords synthetically useful 
vinylogous amides (-enaminones), has been studied in detail in 
order to optimize the reaction conditions, enlarge the scope and 
have insights into the mechanism and the structural features that 
selectively favor the 6-endo dig oxyauration of the triple bond. 
Experimental studies and DFT calculations demonstrate that the 6-
endo dig approach is exclusive with substituted alkynes, whereas 
with terminal alkynes the 5-exo dig cyclization prevails despite the 
large angle (120°) at C6. The same selectivity is observed with N-
Cbz-protected 2-alkynyl piperidines. With these, -amino ketones 
are obtained as a consequence of the 6-endo dig attack to a 
substituted triple bond. Sedamine alkaloids are easily obtained by 
this approach.  
Introduction 
Vinylogous amides (-enaminones) constitute an important class 
of valuable intermediates in the synthesis of heterocyclic and 
natural compounds.[1] They also possess important therapeutic 
potential against the multidrug resistance (MDR) of cancer 
cells,[2] and epilepsy.[3] For these reasons, many efforts have 
been put in the quest for new methods that efficiently provide 
them.[3,4] Among exocyclic vinylogous amides, those built on a 
piperidine ring are versatile intermediates in the preparation of 
many N-heterocycles[5] and natural alkaloids (Figure 1), such as 
desoxoprosophylline,[6] cassine,[7] pinidinone,[8] 
deoxyfebrifugine,[9] norallosedamine[10] and others.[11] The 
synthesis of other related alkaloids such as sedamine[12] and 5-
hydroxy sedamine,[13] halosaline[14] and pelletierine[15] could also 














































Figure 1. Naturally occurring alkaloids prepared from vinylogous amides and 
some related compounds. 
Recently we have reported on a new approach to the synthesis 
of exocyclic vinylogous amides 1 in which the key step was the 
gold(I)-catalyzed rearrangement of N-Boc enynes 2 (Scheme 
1).[11] N-Boc enynes 2 were obtained by the Sonogashira 
coupling of lactam-derived enol phosphates and triflates 3 to a 









X = P(O)(OPh)2, Tf






















Scheme 1. Retrosynthetic analysis. 
The gold(I)-catalyzed step, which was carried out in the 
presence of 2-3 mol % of Ph3PAuOTf in refluxing toluene, 
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included a 6-endo dig attack to the activated triple bond by the 
Boc carbonyl oxygen of the enyne to form a labile cyclic 
urethane intermediate (I). Because of its instability, this 
intermediate could not be usually isolated and thus its hydrolysis 
was carried out in situ to afford the corresponding vinylogous 
amide 1 in good yields (generally no less than 70%, irrespective 
of the R residue) and as the Z isomer only.  
In view of possible applications of the methodology to large 
scale syntheses, we wanted to further lower down the catalyst 
loading. Moreover, concerning the scope of the reaction, this 
was limited to the alkyne chain and so we decided to explore the 
compatibility of various functional groups on the piperidine ring 
with the reaction conditions, as well as to explore the reactivity 
of 7-alkynyl-2,3,4,5-tetrahydro-azepine derivatives. Furthermore, 
we envisaged that a further extension of the scope could be 
attained by the replacement of the N-Boc protection with a N-
Cbz group, which would in theory result in C1' substituted 
vinylogous amides deriving from a carbodeauration step.[16] 
A key point of our previous work was that with substrates such 
as N-Boc enynes 2 the exclusive formation of products deriving 
from a 6-endo dig oxyauration step was observed, whereas for 
N-Boc propargylamines and 2-alkynyl N-Boc-substituted 
pyrrolidines and piperidines[17-19] only the 5-exo dig approach 
has been reported.[20] Also based on other reports from the 
literature, it seemed to us reasonable that in our case the 
alternative 5-exo dig mechanism was disfavored by the larger 
bond angle at C6 (due to the presence of the endocyclic double 
bond), which caused also a much lower reactivity of substrates 2 
in comparison to the corresponding saturated compounds.[18,19] 
However, the strikingly different results reported for the latter 
substrates prompted us to carry out further investigations,  
including theoretical calculations, to unveil the role of the C6 
hybridization, and other possible structural features of these 
substrates, in the 6-endo/5-exo dig preference during the gold-
catalyzed cyclization of enynes 2. Finally, since all natural 
compounds potentially derived from exocyclic vinylogous amides 
(Figure 1) are -amino ketones (or alcohols obtained from -
amino ketones), we decided also to explore the gold(I)-catalyzed 
cycloisomerization of 2-alkynylpiperidines 4 (Scheme 1) as an 
alternative synthetic route in which reduction of the double bond 
to afford the -amino ketone 5 is carried before (and not) after 
the gold-catalyzed step. 
Results and Discussion 
In gold(I)-catalyzed processes the catalyst is generally used at a 
percentage varying from 1 to 5% mol,[21] even though some 
exceptions have also been reported.[22] The active gold(I) 
catalysts are generally prepared in situ by anion exchange 
between LAuX (X = Cl, Br) and a silver salt (AgY) so that the 
highly coordinating anion X- can be eliminated as AgX. Beside 
the fact that the silver does play a role in some gold(I)-catalyzed 
processes,[23] there are issues related to the 
decay/decomposition of the active gold catalyst that have 
recently been pointed out.[24,25] This is what we actually observed 
in our previous study on the gold(I)-catalyzed rearrangement of 
N-Boc-protected 6-alkynyl-3,4-dihydro-2H-pyridines, and for this 
reason we then used 2-3 mol % of the catalyst to achieve a 
complete conversion in a reasonable time.[11] In a study on the 
anion metathesis reported by Bezzenine-Lafollée and 
Gandon,[24] it was found that by slowing down the rate of the 
anion exchange, for example by changing the source of the 
weakly coordinating anion from silver to copper salts, the 
decomposition of the catalyst could be prevented. This was due 
to the slow release of the active LAu+ species in the solution 
over a longer period of time.[26] Among the various catalytic 
systems, Cu(OTf)2 proved to be the best, and so we decided to 
evaluate these new conditions to attain a lower catalyst loading 
(Table 1).  
 
































1 0.5 10 0.5 100 70 
2 0.5 5 0.5 100 72 
3 0.2 5 3.5 76 - 
4 0.1 5 6.5 70 - 
5 0 10 2.5 40 - 
[a] Reactions carried out on a 0.5 mmol scale under inert atmosphere.
   
[b] 
Conversion measured by 
1
H NMR. [c] Yield after chromatographic purification. 
 
We carried out the reaction in refluxing toluene on compound 2 
as a model substrate and lowered the gold(I) relative amount to 
0.5% mol since the first experiment and added Cu(OTf)2 in a 
20:1 molar ratio (entry 1). We were delighted to find out that in 
only 30 minutes the starting material was completely consumed 
and corresponding vinylogous amide 1 was obtained after 
alkaline hydrolysis of intermediate I in the usual 70% yield after 
purification. The same result was obtained with a 10:1 molar 
ratio by lowering the quantity of Cu(OTf)2 to 5% mol (entry 2), 
whereas with lower amounts of Ph3PAuCl the reaction never 
went to completion (entries 3 and 4), even by prolonging the 
reaction time up to 6.5 h (entry 4). Not unexpectedly, Cu(OTf)2 
alone at 10% mol had some catalytic properties[24,27] but the 
reaction required 2.5 h to reach 40% of conversion (entry 5), so 
the cationic gold(I) is the true catalyst. Based on these results, 
we decided to use Ph3PAuCl at 0.5% mol together with 5% mol 
of Cu(OTf)2 as the new catalytic system for the next gold(I)-
catalyzed experiments. 
The synthesis of substrates bearing functional groups on the 
piperidine ring, as well as larger heterocyclic rings, was carried 
out in order to expand the scope of the reaction. 







6a: R = 4-Me
6b: R = 6-Me



































    DCM, -30°C
(b) NaN3, 15-C-5,
    ACN, reflux
8a: R = 4-Me, R' = n-C4H9 
8b: R = 6-Me, R' = n-C4H9
8c: R = (S)-5-OTIPS, R' = n-C4H9
8d: R = (S)-5-OTIPS, R' = Ph
 
Scheme 2. Synthesis of compounds 8a-f. 
We were in particular interested in assessing the compatibility of 
OH groups, usually present in natural compounds prepared from 
-enaminones, and N-containing groups. Lactams 6a[28] and 
6b[29] were obtained by oxidation of the corresponding racemic 
N-Boc protected methylpiperidines,[30,31] whereas lactam 6c 
(Scheme 2) was prepared from (S)-(+)--hydroxymethyl--
butyrolactone[32,33] and using standard chemistry for the final two 
protection steps on the 5-hydroxy--valerolactam.[33] The enol 
phosphates 7a-c were obtained in good yields by treatment of 
6a-c with KHMDS at -78 °C and trapping the enolate in situ by 
addition of diphenyl chlorophosphate; the purification was 
performed on a very short silica pad and the products used as 
substrates in the next Sonogashira coupling with 1-hexyne (to 
give 8a-c, yields 57-74%) or phenylacetylene (to give 8d, yield 
69%). As we have already reported for analogous substrates, 
enynes 8a-d were not stable when neat and were stored in 
solution in the presence of Et3N (1% v/v). Part of enyne 8c was 
deprotected to restore the free hydroxyl group and a portion of 
8e was transformed into the corresponding azide 8f, by 
treatment with mesyl chloride followed by substitution with NaN3. 
More enynes (Scheme 3) were obtained starting from N-Boc -
caprolactam[34] (9) and coupling enolphosphate 10 with 1-hexyne 
(to give 11a), phenylacetylene (to give 11b) and 













11a: R' = n-C4H9 (70%)
11b: R' = Ph (69%)








55 °C, 7 h
 
Scheme 3. Synthesis of compounds 11a-c. 
All enynes 8a-f and 11a-c were successfully used for the 
synthesis of the corresponding vinylogous amides with the gold-
copper catalytic system (Scheme 4). With 8f only the reaction 
was best carried out by using the Ph3PAuCl-AgOTf system to 
provide the corresponding vinylogous amide 12f (which contains 
a masked amino group on the piperidine ring) in good yield after 
purification. As we reported in our previous work, the cyclic 
intermediates were not stable and thus the hydrolysis was 
performed in situ at 80 °C by addition of KOH and tert-butanol.[35] 
In all cases, the vinylogous amides were obtained in good yields 












































    5% Cu(OTf)2,
    toluene,
    reflux, 30 min
(a) 2% Ph3PAuCl,
    2% AgOTf, toluene,







    t-BuOH-toluene, 1:1,
    85 °C, 1 h
(b) KOH, 
    t-BuOH-toluene, 1:1,
    85 °C, 1 h
 
Scheme 4. Synthesis of compounds 12a-i. 
To further expand the scope of the reaction, we then decided to 
focus our attention on different substrates in which a 






carbobenzyloxy replaces the t-butyloxy group. According to the 
reaction mechanism, in the case of N-Boc substrates, once the 
carbonyl oxygen of the Boc group attacks the gold-activated 
triple bond, the so formed t-butyl cation decomposes in 
isobutylene and H+, generating the most important proton-source 
for the protodeauration step. Since carbodeauration has been 
demonstrated with those substrates able to generate a 
carbocation (mainly allylic),[16] we decided to verify if this process 
would be possible in our case with a benzyl carbocation derived 
from a N-Cbz protection, affording thus vinylogous amides 14 












Scheme 5. Planned synthesis of 14. 
The synthesis of N-Cbz enyne 13a (Scheme 6), as the model 
substrate, was carried out by Sonogashira coupling between the 
N-Cbz enol phosphate 15[36] and 1-hexyne. As the analogous N-
Boc compound, also 13a proved unstable when neat and was 







13a R = n-C4H9 (81%)
13b R = Ph (82%)




16a R = n-C4H9 (59%)
16b R = Ph (62%)
16c R = TES (54%)







-20 °C, 2 h
Et3N, CHCl3
55 °C, 7 h
 
Scheme 6. Synthesis of compounds 13a-c and 16a-d. 
Compound 13a was then used in the gold(I)-catalyzed process 
under the usual conditions (Scheme 7) but the reaction failed to 
go to completion even by prolonging the reaction time up to 4.5 
h, as well as to provide, after hydrolysis, compound 14 deriving 
from carbodeauration. Whatever the conditions used, the 
reaction took place via a 6-endo dig oxyauration process and, 
together with the unreacted starting material, we only obtained a 
mixture of vinylogous amides 1 and 17 (Table S1 in the 
Supporting Information), the former deriving from 
protodeauration and the latter from an electrophilic addition of 
the benzylic carbocation to the piperidine double bond (before or 
after the protodeauration step) and consequent release of a 
proton. Moreover, o-benzyltoluene and p-benzyltoluene were 
detected in 1H-NMR of the crude mixture, both deriving from an 
electrophilic aromatic substitution on toluene which therefore 
represents an additional proton source in the process. 
Compounds 1 and 17 were not separated by chromatography, 
but the structure of 17 was easily assigned by 1H NMR analysis 
of the mixture, in which a diagnostic ABX system associated to 
the two benzylic protons (dd at 3.06 ppm, J = 13.5, 4.7 Hz and 
















    Table S1
(b) KOH (6 eq), 
    t-BuOH, 85 °C,



















Scheme 7. Au(I)-catalyzed reaction of 13a. 
Based on these results, we decided to reduce the double bond 
of 13a (to obtain 16a) so that no benzylic addition could occur 
and, by exploiting toluene as a proton source, products formally 
deriving from the double bond reduction of the vinylogous 
amides 1 (i.e. -amino ketones) could instead be obtained 




















O R  
Scheme 8. Planned synthesis of -amino ketones. 
As mentioned above, this would represent an alternative 
synthetic route to -amino ketones in which reduction of the 
double bond is carried out before the gold-catalyzed step. For 
example, a series of natural products which included various 






Sedamine alkaloids has been obtained from -amino ketone 19b 
(Scheme 9),[10] and the latter itself is a natural compound 
(norsedaminone).[37] The selective reduction was performed at 
low temperature with NaBH3CN under acidic conditions
[38] and 
afforded compound 16a in good yield (Scheme 6).  
N
Cbz R
16a R = C4H9















16d R = H
(a) KOH,
     t-BuOH-
     toluene, 1:1












Scheme 9. Synthesis of compounds 19a-b and 21. 
We were glad to observe that the subsequent gold-catalyzed 
step afforded only compound 18a, that derived from the 6-endo 
dig approach, whereas we were unable to find any signal in the 
1H NMR spectrum of the crude reaction mixture attributable to 
the 5-exo dig isomer (Scheme 9).[39] To confirm our findings, we 
decided to synthesize compound 16b by means of a 
Sonogashira coupling of 15 with phenylacetylene followed by 
reduction of the double bond of 13b as already described 
(Scheme 6). Compound 18b is a known compound[40] and since 
it was synthesized by a [4+2] cycloaddition of N-acyliminium ion 
with phenylacetylene, its structure was undoubtedly assigned. 
Treatment of 16b with Ph3PAuCl and Cu(OTf)2 under the usual 
conditions afforded only 18b (Scheme 9), with spectroscopic 
data identical to those reported in the literature.[41] A further 
confirmation of both structures of 18a and 18b came from the 
hydrolysis under basic conditions which afforded -amino 
ketones 19a and 19b which, being quite volatile, were converted 
into their HCl salts in good overall yield (89 and 78%, 
respectively).  
These results seemed in contrast with the data previously 
reported in the literature for N-Boc protected propargylamines, in 
which only 5-exo dig products were obtained even though the 6-
endo dig approach was equally possible. Also when heterocyclic 
substrates were employed, i.e. N-Boc-2-ethynylpyrrolidine,[18,19] 
N-Boc-2-ethynylpiperidine[19] and N-Boc-2-ethynylazepane,[19] 5-
exo dig products were obtained,[20] but all of them had a terminal 
alkyne moiety. Since in our case all substrates possessed a 
substituted alkyne appendage, we wondered whether an 
analogy with the gold(I)-catalyzed propargylic ester migration 
would exist. In the latter, the 1,2-process is favored for terminal 
alkynes whereas the 1,3-rearrangement becomes a competing, 
or even the leading, path for internal ones.[42] The synthesis of 
the substrate with a terminal alkyne was therefore required; this 
was carried out by Sonogashira coupling of phosphate 15 with 
triethylsilylacetylene (to give 13c) followed by reduction of the 
double bond (to give 16c) and deprotection with TBAF (to give 
16d, Scheme 6). It should be highlighted that, in case our 
hypothesis were correct, treatment of 16d with gold-catalyst 
would afford the same product obtained by Gagosz and Buzas 
starting from the analogous N-Boc substrate.[19] We were 
delighted to verify that 16d, under the usual gold catalysis 
conditions, afforded only compound 21 (Scheme 9), which 
derives from a 5-exo dig approach, followed by the isomerization 
of the double bond to the endocyclic position.[43] Furthermore an 
experiment performed with unsaturated N-Boc compound 22 
(Scheme 10) afforded known compound 23,[44] that derives from 
the 5-exo dig intermediate. These results all together show that 
the 6-endo/5-exo dig selectivity we observe with our substrates 









22a R = TMS (79%)



















55 °C, 7 h
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Scheme 10. Synthesis of compound 23. 
To get further insights into the reason for the distinguished 
selectivity with terminal or internal alkynes, and to ascertain 
whether the large N-Csp2-Csp angle has a role in the high 6-endo 
preference with those substrates possessing an internal triple 
bond, DFT calculations were carried out with the Gaussian 09 
suite of programs (see Computational Methods section). Since 
the 5-exo/6-endo selectivity trend does not depend on the 
alkoxycarbonyl moiety, the N-Cbz protection was chosen and 
compounds 13b, 13d, 16b and 16d (Figure 2) were selected as 
model substrates for the cyclization reaction, as examples of the 
four possible combinations of saturated/unsaturated rings and 
substituted/unsubstituted alkynes. Triphenyl-phosphine-gold(I) 
cation was used as reaction catalyst, and the study was 
centered on the cyclization step, which is the regiodetermining 
step. 






















Figure 2. Model substrates for DFT studies. 
Given the very different steric hindrance at the two carbons of 
the triple bond in terminal alkynes (13d and 16d), it would seem 
reasonable to hypothesize at first sight, that steric effects were 
important for the observed 5-exo regioselectivity in these 
substrates, since gold atom could preferably be placed on the 
least substituted terminal position during oxygen attack. But, 
being potentially important, this effect alone would not explain 
the regioselectivity found in internal alkynes (13b and 16b), 
since both carbon atoms are sterically quite similar in those 
cases. Thus, the four alkyne-gold(I) complexes were computed 
(only the unsaturated ones V-Ph and V-H are shown in Figure 3), 
and not surprisingly, the complexes evidenced clear structural 
differences regarding the alkyne/gold complexation. 
  
Figure 3. Structure of complexes V-Ph and V-H. 
Specifically, in V-H, gold coordination induces a weakening of 
the triple bond ( Ca-Cb = 1.23 Å) and a strong asymmetry of the 
C-Au bonds ((Ca-Au) = 2.73 Å, (Cb-Au) = 2.16 Å), forming a 
complex that can be considered to some extent as a vinyl cation. 
The computed natural population atomic charges at both carbon 
atoms are +0.203e (Ca) and -0.480e (Cb), confirming that the 
positive charge of the complex is centered at Ca. These values 
are in agreement with those computed for a simple 
unsubstituted propargylic acetate,[42b] although in our case the 
positive charge on Ca is even higher (+0.203e vs. +0.063e), the 
Ca-Au bond length longer (2.73 vs. 2.514 A) and the Cb-Au bond 
length shorter (2.16 vs. 2.239 Å). On the other hand, the 
alkyne/gold complex V-Ph shows a much more symmetrical 
structure, with nearly identical Au-C distances (Figure 3), and 
NPA charges (Ca = -0.056 e, Cb = -0.002 e). In this case, the 
positive charge is centered in the gold atom (Au = +0.437e in V-
Ph vs  +0.365e in V-H). 
As a result of the higher positive character of the internal Ca 
carbon atom in V-H, the oxygen attack takes place exclusively at 
that position, an experimental fact that could be confirmed 
computationally with substrates 13d and 16d. We found that the 
5-exo dig cyclization occurs with a very low barrier (3.9 kcal/mol 
for TS13-H-5-exo) or, in the case of the corresponding saturated 
compound 16b, with essentially no activation barrier (TS16-H-5-






























G‡ ~ 0.0 kcal/mol G‡ = 5.6 kcal/mol  
Figure 4. Transition state structures and energies for terminal alkynes. 
In fact, no convergence or convergence to the starting material 
was observed during the transition state search in the latter case, 
in spite of the use of different functionals (B3LYP, M06, 
BHandHLYP) and basis sets. To further analyze this issue, a 
potential scan for the O-C bond formation was performed, 
confirming that it is a downhill process without appreciable 
activation energy. On the other hand, the transition states for the 
regioisomeric 6-endo cyclizations were located, presenting low 
but measurable activation energies (8.2 and 5.6 kcal/mol, Figure 
4), which are ca. 4-5 kcal/mol higher than the 5-exo processes. 
This energy difference is able to explain the absolute 
experimental preference for the 5-membered cyclic products, in 
agreement with the preferred 1,2-acyl shift for  propargylic 
acetates  having an unsubstituted alkyne moiety.[42b] 
On the other hand, the transition structures for the reaction of 
the internal triple bonds are in agreement with the experimental 






preference for the Cb attack. Thus, the lowest computed 
activation energies were 7.8 kcal/mol for the unsaturated ring 
(TS13-Ph-6-endo, Figure 5) and 8.4 kcal/mol for TS16-Ph-6-
endo. It is interesting to note, that the endo/exo selectivity is 
predicted to be better for 13 (G‡exo-endo = 2.5 kcal/mol) than for 
16 (G‡exo-endo = 1.3 kcal/mol). This effect can be attributed to 
the increase in the N-C-Ca angle induced by the presence of the 
double bond, from 113º (16d, N-Csp3-Ca) to 119º (13d, N-Csp2-





























G‡ = 9.7 kcal/mol G‡ = 8.4 kcal/mol  
Figure 5. Transition state structures and energies for internal alkynes. 
The data gathered in Figures 3 and 5 are not informative enough 
about the exact reason for the 6-endo selectivity with internal 
alkynes, since Ca and Cb possess very similar electronic 
properties and their bonding distances with the gold atom are 
virtually equal (Figure 3). Thus, we envisioned an indirect way to 
analyze the geometrical factors that determine the reactivity of 
the internal alkynes, by utilizing symmetrical computational 
substrates (Figure 6).  
For example, in the model system VI, the triple bond is 
symmetrically substituted, and both carbons (Ca and Cb) are 
absolutely identical, reducing to the mere geometrical 
preference the factors that affect the formation of one ring or 
another. Interestingly, the activation energy is lower for the 6-
endo cyclization by 4.4 kcal/mol, indicating that in principle, the 
preference for the 6-membered ring is purely geometrical, and 
could be generalized to any type of internal alkynes, regardless 
the substituent at the terminal position. It is worth to mention that 
a similar preference, but to a lesser extent (G‡ = 2.3 kcal/mol) 
was found for the computational model VII, possessing 
saturated rings, in agreement with the general lower selectivity 
























G‡5-exo   = 13.0 kcal/mol G
‡
6-endo = 8.6 kcal/mol
BnO2C
VI
VII G‡5-exo   = 5.0 kcal/mol G
‡






Figure 6. Comparison of the activation energies for the 5-exo and 6-endo dig 
pathways. 
Conclusions 
In this work we have studied in detail the gold(I)-catalyzed 
cyclization of N-Boc-protected 6-alkynyl-3,4-dihydro-2H-
pyridines, which provides synthetically useful exocyclic 
vinylogous amides, with three objectives in mind. First, in view of 
large scale application of the methodology, we wanted to 
optimize the reaction conditions in order to reduce as much as 
possible the amount of gold-catalyst. This has been realized by 
using Cu(OTf)2 as the triflate source, which allowed us to charge 
the reaction vessel with 0.5 mol % of Au(I) without affecting the 
reaction rate. Secondly, we expanded the scope of the reaction 
to substituted and different N-heterocycles to assess the 
tolerance to the reaction conditions by some functional groups 
usually present in natural compounds easily prepared by these 
vinylogous amides. Third goal was to assess the structural 
features that selectively favors the 6-endo dig oxyauration of the 
triple bond. We found that a 6-endo dig approach is exclusive 
with substituted alkynes, whereas with terminal alkynes the 5-
exo dig cyclization prevails despite the large angle (120°) at C6. 
Analogous selectivity is observed with N-Cbz-protected 2-alkynyl 
piperidines. These, after hydrolysis of the cyclic intermediates, 
furnish -amino ketones as a consequence of a 6-endo dig 
attack to the internal triple bond. DFT calculations showed that 
with both types of substrates, the oxyauration step has low or 
almost no barrier when involves the internal position of a 
terminal triple bond, thus determining a 5-exo dig process. By 
contrast, the 6-endo dig approach is always favored with 
substituted alkynes, this preference being purely geometrical 
and irrespective of the type of substitution, thus providing either 






-enaminones or their reduced equivalents -amino ketones in a 
robust, reliable and convenient way.  
Experimental Section 
General. Chromatographic separations were performed under pressure 
on silica gel by flash-column techniques; Rf values refer to TLC carried 
out on 0.25-mm silica gel plates (F254), with the same eluent as indicated 
for the column chromatography. 1H NMR spectra were recorded at 200 or 
400 MHz and 13C NMR spectra were recorded at 50.33 or 100.4 MHz, 
both in CDCl3 solution, unless otherwise specified. Solvent reference line 
was set at 7.26 (CDCl3) or 4.79 ppm (D2O). Mass spectra were either 
recorded at an ionizing voltage of 70 eV or carried out by direct inlet of a 
10 ppm solution in CH3OH on a LCQ Fleet
TM Ion Trap LC/MS system 
with an electrospray ionization (ESI) interface in the positive mode. 
Microanalyses were carried out with an elemental analyzer. Compounds 
6a,[28] 6b,[29] 10,[34] 15[36] and 5-hydroxy--valerolactam[32] were prepared 
as reported. All enynes 2, 8, 11, 13, and 22, as well as intermediates 16 
decompose when neat and must be stored in solution in the presence of 
Et3N (1% v/v). 
Computational Methods 
The structures were optimized by using density functional theory (DFT) 
with the BHandHLYP[45] and the 6-31G* (LANL2DZ for Au) basis set as 
implemented in Gaussian 09.[46] The B3LYP functional was also 
evaluated, affording similar results to BHandHLYP, but some of the 
lowest-in-energy transition states (TS13-H-5-exo and TS16-H-5-exo) did 
not converge properly with the former. The energy values shown in 
Figures 3[47] and 4 also include single-point refinements at M06-2X/6-
311++G**(SDD) level of theory[48] on the previously optimized structures, 
to better account for the dispersion forces of such large systems. The 
stationary points were characterized by frequency calculations in order to 
verify that they have the right number of imaginary frequencies. The 
intrinsic reaction coordinates (IRC)[49] were followed to verify the energy 
profiles connecting each TS to the correct associated local minima. 
Natural bond orbital (NBO) analysis[50]  has been performed to evaluate 
the NPA atomic charges. 
(5S)-2-Oxo-5-triisopropylsilanyloxy-piperidine-1-carboxylic acid tert-
butyl ester (6c). 5-Hydroxy--valerolactam[32] (680 mg, 5.9 mmol) was 
dissolved in anhydrous DMF (12 mL); imidazole (1.21 mg, 17.7 mmol) 
and triisopropylsilyl chloride (1.27 mL, 5.9 mmol) were added to this 
solution that, after the addition, was warmed at 40 °C. A second 
equivalent of triisopropylsilyl chloride (1.27 mL, 5.9 mmol) was added in 
portions over 8 h and the reaction left under stirring at 40 °C overnight. 
After cooling to room temperature, water was added (120 mL), the 
product extracted with Et2O (4 x 50 mL) and the combined organic 
phases were dried over anhydrous Na2SO4. After filtration and 
evaporation of the solvent, the crude was purified by flash 
chromatography (eluent: EtOAc; Rf 0.27), affording pure 5-
triisopropylsilanyloxypiperidin-2-one as a colorless oil (1.36 g, 85%). 
[α]D
21 = ‒ 11.3 (c 1.12, CHCl3). 
1H NMR (400 MHz) δ (ppm): 7.05 (br s, 1 
H, N-H), 4.17-4.12 (m, 1 H, 5-H), 3.41-3.37 (m, 1 H, 6-H), 3.23-3.19 (m, 1 
H, 6-H'), 2.56 (dt, J = 17.6, 7.6 Hz, 1 H, 3-H), 2.27 (dt, J = 17.6, 6.1 Hz, 1 
H, 3-H'), 1.90-1.86 (m, 2 H, 4-H), 1.05-0.98 (m, 21 H, TIPS). 13C NMR 
(100.4 MHz) δ (ppm): 172.1 (s, C2), 64.1 (d, C5), 49.4 (t, C6), 29.0 (t, 
C3), 27.5 (t, C4), 17.9 (q, 6 C, CH3 TIPS), 12.1 (d, 3 C, CH TIPS). MS 
(ESI) m/z (%): 565 ([2M+Na]+, 100), 543 ([2M+1]+, 16). C14H29NO2Si 
(271.47): calcd C, 61.94; H, 10.77; N, 5.16. Found: C, 61.72; H, 10.50; N, 
4.91. 5-Triisopropylsilanyloxypiperidin-2-one (1.3 g, 4.79 mmol) was 
dissolved in anhydrous CH2Cl2 (30 mL); to this solution Et3N (740 L, 
5.27 mmol), di-t-butyl dicarbonate (1.1 g, 4.79 mmol) and DMAP (59 mg, 
0.48 mmol) were added and the resulting mixture was heated under 
reflux. After 2 h, a second equivalent of di-t-butyl dicarbonate (1.1 g, 4.79 
mmol) was added and, after the reaction was completed (TLC; 5 h), the 
mixture was cooled to room temperature, water was added (40 mL) and 
the layers separated; the aqueous one was extracted with CH2Cl2 (3 x 20 
mL) and the combined organic extracts were washed with aq. 5% KHSO4 
(40 mL), satd NaHCO3 (40 mL), water (40 mL), brine (40 mL) and finally 
dried over anhydrous Na2SO4. The solvent was filtered and evaporated 
and the crude purified by flash chromatography (eluent: n-hexane-EtOAc, 
8:1; Rf 0.12), affording pure 6c as a colorless oil (1.44 g, 81%). [α]D
20 = 
+10.0 (c 0.92, CHCl3). 
1H NMR (400 MHz) δ (ppm): 4.26-4.21 (m, 1 H, 5-
H), 3.73 (dd, J = 13.1, 4.7 Hz, 1 H, 6-H), 3.62 (dd, J = 13.1, 3.5 Hz, 1 H, 
6-H'), 2.75-2.67 (m, 1 H, 3-H), 2.40 (dt, J = 17.2, 5.9 Hz, 1 H, 3-H'), 1.98-
1.92 (m, 1 H, 4-H), 1.91-1.84 (m, 1 H, 4-H'), 1.48 (s, 9 H, C(CH3)3), 1.10-
0.95 (m, 21 H, TIPS). 13C NMR (100.4 MHz) δ (ppm): 170.8 (s, C2), 
152.3 (s, C=O), 82.7 (s, C(CH3)3), 64.4 (d, C5), 52.5 (t, C6), 31.0 (t, C3), 
29.1 (t, C4), 27.9 (q, 3 C, CH3 Boc), 17.8 (q, 6 C, CH3 TIPS), 12.0 (d, 3 C, 
CH TIPS). MS (ESI) m/z (%): 766 (33), 765 ([2M + Na]+, 100), 394 ([M + 
Na]+, 7). C19H37NO4Si (371.59): calcd C, 61.41; H, 10.04; N, 3.77. Found: 
C, 61.25; H, 9.98; N, 3.91. 
(±)-6-(Diphenoxyphosphoryloxy)-4-methyl-3,4-dihydro-2H-pyridine-
1-carboxylic acid tert-butyl ester (7a). A 0.5 M solution of KHMDS in 
toluene (6.4 mL, 3.2 mmol) was diluted in anhydrous THF (18 mL) and 
cooled at ‒ 78 °C. A solution of 6a[28] (455 mg, 2.13 mmol) in anhydrous 
THF (10 mL) was then added dropwise, keeping the temperature below 
‒ 70 °C, and the resulting mixture was stirred for 1.5 h. 
Diphenylchlorophosphate (663 L, 3.2 mmol) was slowly added, and 
after 1 h, the mixture was allowed to warm at 0 °C and quenched by the 
addition of aqueous 10% NaOH (50 mL). The product was extracted with 
Et2O (3 x 40 mL) and the combined organic extracts were washed once 
with aqueous 10% NaOH (28 mL) and dried over anhydrous K2CO3. After 
filtration and evaporation of the solvent, the crude material was purified 
over a short pad of silica gel (eluent: n-hexane/EtOAc 7:1 + 1% Et3N; Rf 
0.13), affording pure 7a as a colourless oil (800 mg, 85%). 1H NMR (400 
MHz) δ (ppm): 7.37-7.31 (m, 4 H, Ar), 7.25-7.17 (m, 6 H, Ar), 5.01-4.99 
(m, 1 H, 5-H), 3.61-3.50 (m, 2 H, 2-H), 2.45-2.38 (m, 1 H, 4-H), 1.87-1.79 
(m, 1 H, 3-H), 1.43 (s, 9 H, C(CH3)3), 1.41-1.33 (m, 1 H, 3-H'), 1.01 (d, J 
= 6.0 Hz, 3 H, CH3). 
13C NMR (100.4 MHz) δ (ppm): 153.1 (s, C=O), 
150.6 (s, Ph), 150.5 (s, Ph), 140.0 (s, C6), 129.7 (d, 4 C, CAr), 125.4 (d, 
Ph), 125.3 (d, Ph), 120.09 (d, Ph), 120.08 (d, Ph), 120.04 (d, Ph), 120.03 
(d, Ph), 105.3 (d, C5), 81.7 (s, C(CH3)3), 44.1 (t, C2), 31.1 (d, C4), 28.1 
(q, 3 C, C(CH3)3), 27.8 (t, C3), 21.3 (q, CH3). MS (ESI) m/z (%): 913 
([2M+Na]+, 100), 468 ([M+Na]+, 20), 446 ([M+1]+, 35). 
(±)-6-(Diphenoxyphosphoryloxy)-2-methyl-3,4-dihydro-2H-pyridine-
1-carboxylic acid tert-butyl ester (7b). Prepared as reported for 7a, 
starting from 6b[29] (362 mg, 1.7 mmol) and obtaining, after purification 
(eluent: n-hexane-EtOAc 6:1 + 1% Et3N; Rf 0.12), pure 7b (658 mg, 87%) 
as clear yellowish oil. 1H NMR (400 MHz) δ (ppm): 7.38-7.28 (m, 4 H, Ph), 
7.26-7.12 (m, 6 H, Ph), 5.11 (q, J = 3.5 Hz, 1 H, 5-H), 4.67-4.53 (m, 1 H, 
2-H), 2.21-2.10 (m, 2 H, 4-H), 1.77-1.66 (m, 1 H, 3-H), 1.63-1.57 (m, 1 H, 
3-H'), 1.43 (s, 9 H, C(CH3)3), 1.15 (d, J = 6.9 Hz, 3 H, CH3). 
13C NMR 
(100.4 MHz) δ (ppm): 153.2 (s, C=O), 150.5 (s, Ph), 150.4 (s, Ph), 138.3 
(s, C6), 129.7 (d, 4 C, Ph), 125.4 (d, Ph), 125.3 (d, Ph), 120.12 (d, Ph), 
120.10 (d, Ph), 119.98 (d, Ph), 119.93 (d, Ph), 99.3 (d, C5), 81.6 (s, 
C(CH3)3), 49.2 (d, C2), 28.1 (q, 3 C, C(CH3)3), 27.1 (t, C4), 18.6 (t, C3), 
15.7 (q, CH3). MS (ESI) m/z (%): 913 ([2M+Na]
+, 100), 468 ([M+Na]+, 41), 
446 ([M+1]+, 27). 
(3S)-6-(Diphenoxyphosphoryloxy)-3-triisopropylsilanyloxy-3,4-
dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (7c). Prepared 
as reported for 7a, starting from 6c (1.44 g, 3.87 mmol) and obtaining, 






after purification (eluent: n-hexane/EtOAc 5:1 + 1% Et3N; Rf 0.50), pure 
7c (2.33 g, 99%) as pale yellow oil. 1H NMR (400 MHz) δ (ppm): 7.37 (m, 
4 H, Ph), 7.27-7.25 (m, 4 H, Ph), 7.21-7.18 (m, 2 H, Ph), 5.06-5.04 (m, 1 
H, 5-H), 4.11-4.06 (m, 1 H, 3-H), 3.71 (dd, J = 12.9, 3.1 Hz, 1 H, 2-H), 
3.51 (dd, J = 12.9, 7.4 Hz, 1 H, 2-H'), 2.51-2.43 (m, 1 H, 4-H), 2.16-2.08 
(m, 1 H, 4-H'), 1.44 (s, 9 H, C(CH3)3), 1.13-1.01 (m, 21 H, TIPS). 
13C 
NMR (100.4 MHz) δ (ppm): 153.0 (s, C=O), 150.5 (s, 2 C, CAr), 140.0 (s, 
C6), 129.7 (d, 4 C, CAr), 125.4 (d, 2 C, CAr), 120.0 (d, 4 C, CAr), 97.8 (d, 
C5), 81.6 (s, C(CH3)3), 65.2 (d, C3), 51.2 (t, C2), 32.4 (t, C4), 28.0 (q, 3 C, 
CH3 Boc), 17.9 (q, 6 C, CH3 TIPS), 12.1 (d, 3 C, CH TIPS). MS (ESI) m/z 
(%): 1229 ([2M+Na]+, 100), 792 ([M+Na]+, 7). 
General Procedure for Sonogashira Coupling. Phosphate (7a-c, 
10,[34] 15[36]) was dissolved in an anhydrous 3:1 Et3N/CHCl3 mixture (0.13 
M), and the alkyne (1 mmol), CuI (0.1 mmol), and (Ph3P)2PdCl2 (0.05 
mmol) were added. The resulting solution was heated at 55 °C (external) 
for 2 h, after which time a second portion of alkyne (0.5 mmol), CuI (0.05 
mmol) and (Ph3P)2PdCl2 (0.025 mmol) were added, if necessary. The 
mixture was heated at 55 °C until completion (TLC, usually in 4-7 h). 
After cooling to room temperature, water (12 mL) was added and the 
product extracted with Et2O (3 x 12 mL); the combined organic extracts 
were dried over anhydrous K2CO3. After filtration and evaporation of the 
solvent, crude enyne (8a-d, 11a-c, 13a-c) was purified by flash 
chromatography (eluent containing 1% Et3N) and stored at 4 °C as a 0.1 
M solution in the eluent until use.  
(±)-6-Hex-1-ynyl-4-methyl-3,4-dihydro-2H-pyridine-1-carboxylic acid 
tert-butyl ester (8a). Pale yellow oil (205 mg, 74%). Rf 0.12 (n-
hexane/EtOAc 30:1 + 1% Et3N). 
1H NMR (400 MHz) δ (ppm): 5.34 (d, J = 
3.5 Hz, 1 H, 5-H), 3.59 (ddd, J = 12.9, 7.0, 3.1 Hz, 1 H, 2-H), 3.46 (ddd, J 
= 12.9, 8.2, 2.7 Hz, 1 H, 2-H'), 2.36-2.30 (m, 1 H, 4-H), 2.30 (t, J = 7.0 Hz, 
2 H, 3'-H), 1.88-1.83 (m, 1 H, 3-H'), 1.55-1.46 (m, 2 H, 4'-H), 1.49 (s, 9 H, 
C(CH3)3), 1.44-1.36 (m, 3 H, 5'-H and 3-H), 1.00 (d, J = 7.0 Hz, 3 H, CH3), 
0.90 (t, J = 7.4 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm):  153.1 (s, 
C=O), 126.7 (d, C5), 121.4 (s, C6), 88.3 (s, C1'), 80.7 (s, C(CH3)3), 77.6 
(s, C2'),  42.2 (t, C2), 30.9 (t, C3), 30.7 (d, C4), 29.0 (t, C3'), 28.3 (q, 3 C, 
CH3 Boc), 22.0 (q, CH3), 21.0 (t, C4'), 19.1 (t, C5'), 13.6 (q, C6'). MS 
(ESI) m/z (%): 577 ([2M+Na]+, 100), 300 ([M+Na]+, 30). MS/MS (ESI of 
[M+Na]+) m/z (%): 300 (4), 244 (100). 
(±)-6-Hex-1-ynyl-2-methyl-3,4-dihydro-2H-pyridine-1-carboxylic acid 
tert-butyl ester (8b). Yellow oil (160 mg, 58%). Rf 0.18 (n-hexane/EtOAc 
30:1 + 1% Et3N). 
1H NMR (400 MHz) δ (ppm): 5.44 (t, J = 3.7 Hz, 1 H, 5-
H), 4.56-4.49 (m, 1 H, 2-H), 2.30 (t, J = 7.0 Hz, 2 H, 3'-H), 2.15-2.09 (m, 
2 H, 4-H), 1.83-1.73 (m, 1 H, 3-H), 1.62-1.55 (m, 1 H, 3-H'), 1.49 (s, 9 H, 
C(CH3)3), 1.55-1.38 (m, 4 H, 4'-H and 5'-H), 1.11 (d, J = 6.7 Hz, 3 H, 
CH3), 0.90 (t, J = 7.3 Hz, 3 H, 6'-H). 
13C NMR (100.4 MHz) δ (ppm): 
153.0 (s, C=O), 119.9 (d, C5), 119.8 (s, C6), 87.6 (s, C1'), 80.6 (s, 
C(CH3)3), 78.3 (s, C2'), 46.8 (d, C2), 30.7 (t, C4'), 28.3 (q, 3 C, CH3 Boc), 
27.0 (t, C3), 22.1 (t, C5'), 19.8 (t, C4), 19.1 (t, C3'), 15.9 (q, CH3), 13.6 (q, 
C6'). MS/MS (ESI of [M+Na]+) m/z (%):  300 (3), 244 (100). 
(3S)-6-Hex-1-ynyl-3-triisopropylsilanyloxy-3,4-dihydro-2H-pyridine-
1-carboxylic acid tert-butyl ester (8c). Yellow oil (279 mg, 64%). Rf 
0.36 (n-hexane/EtOAc 20:1 + 1% Et3N). [α]D
19 = +37.9 (c 0.77, CHCl3). 
1H NMR (400 MHz) δ (ppm): 5.40 (t, J = 4.0 Hz, 1 H, 5-H), 4.05-3.99 (m, 
1 H, 3-H),  3.84 (dd, J = 12.4, 3.0 Hz, 1 H, 2-H), 3.21 (dd, J = 12.4, 8.4 
Hz, 1 H, 2-H'), 2.44 (dt, J = 18.9, 5.2 Hz, 1 H, 4-H), 2.31 (t, J = 7.0 Hz, 2 
H, 3'-H), 2.08 (ddd, J = 18.9, 6.3, 4.0 Hz, 1 H, 4-H'), 1.53-1.46 (m, 2 H, 
4'-H), 1.48 (s, 9 H, C(CH3)3), 1.44-1.39 (m, 2 H, 5'-H), 1.07-1.04 (m, 21 H, 
TIPS), 0.90 (t, J = 7.3 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm): 
152.9 (s, C=O), 122.2 (s, C6), 119.2 (d, C5), 88.7 (s, C1'), 80.7 (s, 
C(CH3)3), 77.3 (s, C2'), 65.2 (d, C3), 49.8 (t, C2), 34.5 (t, C4), 30.7 (t, 
C3'), 28.1 (q, 3 C, CH3 Boc), 22.0 (t, C4'), 19.1 (t, C5'), 18.0 (q, 6 C, CH3 
TIPS), 13.6 (q, C6'), 12.1 (d, 3 C, CH TIPS). MS (ESI) m/z (%): 909 
([2M+K]+, 43), 893 ([2M+Na]+, 100), 458 ([M+Na]+, 26). 
(3S)-6-Phenylethynyl-3-triisopropylsilanoxy-3,4-dihydro-2H-
pyridine-1-carboxylic acid tert-butyl ester (8d). Yellow oil (314 mg, 
69%). Rf 0.13 (n-hexane/EtOAc 20:1 + 1% Et3N). [α]D
27 = +22.5 (c 2.03, 
CHCl3). 
1H NMR (400 MHz) δ (ppm): 7.45-7.32 (m, 2 H, Ph), 7.33-7.27 
(m, 3 H, Ph), 5.60 (t, J = 4.1 Hz, 1 H, 5-H), 4.13-4.08 (m, 1 H, 3-H), 3.87 
(dd, J = 12.5, 2.7 Hz, 1 H, 2-H), 3.36 (dd, J = 12.5, 8.0 Hz, 1 H, 2-H'), 
2.53 (dt, J = 19.1, 5.3 Hz, 1 H, 4-H), 2.18 (ddd, J = 19.1, 5.6, 4.1 Hz, 1 H, 
4-H'), 1.49 (s, 9 H, C(CH3)3), 1.11-1.02 (m, 21 H, TIPS). 
13C NMR (100.4 
MHz) δ (ppm): 153.0 (s, C=O), 131.3 (d, 2 C, Ph), 128.3 (d, 2 C, Ph), 
128.0 (d, Ph), 123.3 (s, C6), 122.1 (s, Ph), 120.5 (d, C5), 87.8 (s, C1'), 
86.3 (s, C2'), 81.1 (s, C(CH3)3), 65.1 (d, C3), 50.0 (t, C2), 34.7 (t, C4), 
28.2 (q, 3 C, CH3 Boc), 18.0 (q, 6 C, CH3 TIPS), 12.3 (d, 3 C, CH TIPS). 
MS (ESI) m/z (%): 933 ([2M+Na]+, 100), 478 ([M+Na]+, 12), 456 ([M+1]+, 
11). 
6-Trimethylsilanylethynyl-3,4-dihydro-2H-pyridine-1-carboxylic acid 
tert-butyl ester (22a). Colorless oil (229 mg, 82%). Rf 0.63 (Petroleum 
ether/EtOAc 9:1 + 1% Et3N). 
1H NMR (200 MHz) δ (ppm): 5.63 (t, J = 4.0 
Hz, 1 H, 5-H), 3.57-3.52 (m, 2 H, 2-H), 2.16 (td, J = 6.9, 4.1 Hz, 2 H, 4-H), 
1.83-1.71 (m, 2 H, 3-H), 1.52 (s, 9 H, C(CH3)3), 0.19 (s, 9 H, Si(CH3)3). 
13C NMR (50.33 MHz) δ (ppm): 153.2 (s, C=O), 124.0 (s, C6), 122.5 (d, 
C5), 101.9 (s, C2'), 91.9 (s, C1'), 81.4 (s, C(CH3)3), 43.2 (t, C2), 28.3 (q, 
3 C, CH3 Boc), 23.7 (t, C3), 22.7 (t, C4), -0.1 (q, 3 C, Si(CH3)3). MS m/z 
(%): 279 ([M]+, 23), 223 (92), 206 (15), 179 (87), 178 (100), 164 (72), 57 
(56). 
6-Hex-1-ynyl-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester 
(13a). Colorless oil (720 mg, 81%). Rf 0.11 (n-hexane/EtOAc 20:1 + 1% 
Et3N). 
1H NMR (400 MHz) δ (ppm): 7.42-7.27 (m, 5 H), 5.52 (t, J = 3.9 Hz, 
1 H, 3-H), 5.20 (s, 2 H, CH2Ph), 3.65-3.62 (m, 2 H, 6-H), 2.21-2.13 (m, 4 
H, 4-H and 3'-H), 1.82-1.75 (m, 2 H, 5-H), 1.45-1.31 (m, 4 H, 4'-H and 5'-
H), 0.87 (t, J = 7.0 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm): 153.9 
(s, C=O), 136.4 (s, Ph), 128.3 (d, 2 C, Ph), 127.9 (d, 2 C, Ph), 127.8 (d, 
Ph), 122.2 (s, C6), 121.9 (d, C5), 89.1 (s, C1'), 77.1 (s, C2'), 67.5 (t, 
CH2Ph), 44.0 (t, C2), 30.6 (t, C4'), 23.5 (t, C4), 22.6 (t, C3), 22.0 (t, C5'), 
18.9 (t, C3'), 13.6 (q, C6'). MS (ESI) m/z (%): 617 ([2M+Na]+, 100), 320 
([M+Na]+, 12), 298 [M+1]+, 31). 
6-Phenylethynyl-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl 
ester (13b). Pale yellow oil (260 mg, 82%). Rf 0.21 (n-hexane/EtOAc 
20:1 + 1% Et3N). 
1H NMR (400 MHz) δ (ppm): 7.42-7.39 (m, 2 H, Ph), 
7.29-7.23 (m, 8 H, Ph), 5.73 (t, J = 4.1 Hz, 1 H, 5-H), 5.24 (s, 2 H, 
CH2Ph), 3.73-3.70 (m, 2 H, 2-H), 2.25 (td, J = 6.8, 4.1 Hz, 2 H, 4-H), 
1.88-1.83 (m, 2 H, 3-H). 13C NMR (100.4 MHz) δ (ppm): 153.9 (s, C=O), 
136.2 (s, Ph), 131.4 (d, 2 C, Ph), 128.4 (d, 2 C, Ph), 128.1 (d, 2 C, Ph), 
128.04 (d, 2 C, Ph), 128.02 (d, Ph), 127.9 (d, Ph), 123.4 (d, C5), 123.1 (s, 
C6), 122.0 (s, Ph), 88.1 (s, C1'), 86.1 (s, C2'), 67.8 (t, CH2Ph), 44.0 (t, 
C2), 23.7 (t, C3), 22.5 (t, C4). MS (ESI) m/z (%): 657 ([2M+Na]+, 100), 
318 [M+1]+, 30). 
6-Triethylsilanylethynyl-3,4-dihydro-2H-pyridine-1-carboxylic acid 
benzyl ester (13c). Colorless oil (709 mg, 82%). Rf 0.25 (n-
hexane/EtOAc 20:1 + 1% Et3N). 
1H NMR (400 MHz) δ (ppm): 7.42-7.40 
(m, 2 H, Ph), 7.39-7.28 (m, 3 H, Ph), 5.70 (t, J = 4.1 Hz, 1 H, 5-H), 5.21 
(s, 2 H, CH2Ph), 3.65-3.62 (m, 2 H, 2-H), 2.18 (td, J = 6.6, 4.1 Hz, 2 H, 4-
H), 1.82-1.72 (m, 2 H, 3-H), 0.96 (t, J = 8.0 Hz, 9 H, Si(CH2CH3)3), 0.57 
(q, J = 8.0 Hz, 6 H, Si(CH2CH3)3). 
13C NMR (100.4 MHz) δ (ppm): 153.9 
(s, C=O), 136.5 (s, Ph), 128.3 (d, 2 C, Ph), 127.8 (d, 2 C, Ph), 127.7 (d, 
Ph), 124.5 (s, C6), 122.0 (d, C5), 102.2 (s, C2'), 90.6 (s, C1'), 67.3 (t, 
CH2Ph), 43.8 (t, C2), 23.6 (t, C3), 22.5 (t, C4), 7.4 (q, 3 C, Si(CH2CH3)3), 






4.3 (t, 3 C, Si(CH2CH3)3). MS (ESI) m/z (%): 733 ([2M+Na]
+, 100), 356 
[M+1]+, 30). 
7-Hex-1-ynyl-2,3,4,5-tetrahydroazepine-1-carboxylic acid tert-butyl 
ester (11a). Colorless oil (194 mg, 70%). Rf 0.24 (eluent: n-
hexane/EtOAc 20:1 + 1% Et3N). 
1H NMR (200 MHz) δ (ppm): 5.81 (t, J = 
6.6 Hz, 1 H, 6-H), 3.42 (t, J = 5.3 Hz, 2 H, 2-H), 2.28 (t, J = 6.8 Hz, 2 H, 
3'-H), 2.19-2.10 (m, 2 H, 5-H), 1.78-1.66 (m, 2 H, 4-H), 1.66-1.35 (m, 6 H, 
3-H, 4'-H and 5'-H), 1.46 (s, 9 H, C(CH3)3), 0.89 (t, J = 6.9 Hz, 3 H, 6'-H). 
13C NMR (50.33 MHz) δ (ppm): 153.6 (s, C=O), 131.0 (s, C7), 127.8 (d, 
C6), 87.3 (s, C2'), 80.0 (s, C(CH3)3), 78.5 (s, C1'), 47.2 (t, C2), 30.7 (t, 
C4'), 29.6 (t, C3), 28.3 (q, 3 C, C(CH3)3), 27.5 (t, C4), 23.8 (t, C3'), 22.0 (t, 
C5), 19.0 (t, C5'), 13.5 (q, C6'). MS m/z (%): 277 ([M]+, 4), 221 (61), 179 
(68), 162 (65), 148 (57), 135  (87), 57 (100). 
7-Phenylethynyl-2,3,4,5-tetrahydroazepine-1-carboxylic acid tert-
butyl ester (11b). Yellow oil (205 mg, 69%). Rf 0.21 (eluent: n-
hexane/EtOAc 20:1 + 1% Et3N). 
1H NMR (200 MHz) δ (ppm): 7.44-7.37 
(m, 2 H, Ph), 7.32-7.28 (m, 3 H, Ph), 6.02 (t, J = 6.6 Hz, 1 H, 6-H), 3.54-
3.49 (m, 2 H, 2-H), 2.29-2.20 (m, 2 H, 5-H), 1.83-1.72 (m, 2 H, 4-H), 
1.58-1.45 (m, 2 H, 3-H), 1.48 (s, 9 H, C(CH3)3). 
13C NMR (50.33 MHz) δ 
(ppm): 153.3 (s, C=O), 132.4 (d, Ph), 131.1 (d, 2 C, Ph), 128.1 (d, 2 C, 
Ph), 127.8 (d, C6), 127.3 (s, Ph), 123.0 (s, C7), 87.5 (s, C2'), 86.4 (s, 
C1'), 80.1 (s, C(CH3)3), 47.2 (t, C2), 29.4 (t, C3), 28.2 (q, 3 C, C(CH3)3), 
27.6 (t, C4), 23.6 (t, C5). MS m/z (%): 297 ([M]+, 3), 241 (100), 197 (67), 
196 (99), 182 (47), 169 (54). 
7-Cyclopropylethynyl-2,3,4,5-tetrahydroazepine-1-carboxylic acid 
tert-butyl ester (11c). Colorless oil (196 mg, 75%). Rf 0.30 (eluent: n-
hexane/EtOAc 20:1 + 1% Et3N). 
1H NMR (200 MHz) δ (ppm): 5.81 (t, J = 
6.5 Hz, 1 H, 6-H), 3.44-3.39 (m, 2 H, 2-H), 2.18-2.09 (m, 2 H, 5-H), 1.77-
1.66 (m, 2 H, 4-H), 1.52-1.40 (m, 2 H, 3-H), 1.47 (s, 9 H, C(CH3)3), 1.37-
1.24 (m, 1 H, 3'-H), 0.83-0.64 (m, 4 H, 4'-H). 13C NMR (50.33 MHz) δ 
(ppm): 153.5 (s, C=O), 131.0 (d, C6), 127.7 (s, C7), 90.2 (s, C2'), 80.0 (s, 
C(CH3)3), 73.9 (s, C1'), 47.3 (t, C2), 29.6 (t, C5), 28.4 (q, 3 C, C(CH3)3), 
27.5 (t, C4), 23.8 (t, C3), 8.2 (t, 2 C, C4'), -0.1 (d, C3'). MS m/z (%): 261 
([M]+, 10), 205 (100), 204 (41), 160 (44), 57 (43). 
(3S)-6-Hex-1-ynyl-3-hydroxy-3,4-dihydro-2H-pyridine-1-carboxylic 
acid tert-butyl ester (8e). To a solution of 8c (740 mg, 1.7 mmol) in 
anhydrous THF (82 mL), under N2 atmosphere, 1 M TBAF solution in 
THF (1.94 mL, 1.94 mmol) was slowly added. After 30 min the solvent 
was evaporated under vacuum and the residue was taken up in Et2O (82 
mL). The solvent was evaporated again and the residue was purified by 
flash chromatography (n-hexane/EtOAc 2:1 + 1% Et3N; Rf 0.24) to afford 
pure 8e (410 mg, 86%). [α]D
22 = ‒ 10.6 (c 0.97, CHCl3). 
1H NMR (400 
MHz) δ (ppm): 5.40 (t, J = 3.9 Hz, 1 H, 5-H), 4.07-4.02 (m, 1 H, 3-H), 
3.56 (AB system, JAB = 12.8 Hz, 1 H, 2-H), 3.54 (AB system, JAB = 12.8 
Hz, 1 H, 2-H'), 2.53 (br s, 1 H, OH), 2.44 (dt, J = 19.1, 4.3 Hz, 1 H, 4-H), 
2.29 (t, J = 7 Hz, 2 H, 3'-H), 2.09 (dt, J = 19.1, 4.7 Hz, 1 H, 4-H'), 1.54-
1.45 (m, 2 H, 4'-H), 1.47 (s, 9 H, C(CH3)3), 1.44-1.36 (m, 2 H, 5'-H), 0.89 
(t, J = 7.4 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm): 153.8 (s, C=O), 
122.4 (s, C6), 118.6 (d, C5), 88.8 (s, C1'), 81.2 (s, C(CH3)3), 77.0 (s, C2'), 
64.3 (d, C3), 49.2 (t, C2), 32.8 (t, C4), 30.6 (t, C4'), 28.2 (q, 3 C, CH3 
Boc), 22.0 (t, C3'), 19.0 (t, C5'), 13.6 (q, C6'). MS (ESI) m/z (%): 597 
([2M+K]+, 24), 581 ([2M+Na]+, 100), 302 ([M+Na]+, 21). 
6-Ethynyl-3,4-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
(22b). Prepared as reported for 8e, starting from 22a (279 mg, 1.0 mmol) 
and obtaining, after purification by flash chromatography (eluent: 
petroleum ether/EtOAc 9:1; Rf 0.50), pure 22b (205 mg, 99%) as a 
colorless oil. 1H NMR (200 MHz) δ (ppm): 5.65 (t, J = 4.0 Hz, 1 H, 5-H), 
3.59-3.54 (m, 2 H, 2-H), 2.93 (s, 1 H, 2'-H), 2.21-2.12 (m, 2 H, 4-H), 1.84-
1.72 (m, 2 H, 3-H), 1.50 (s, 9 H, C(CH3)3). 
13C NMR (50.33 MHz) δ 
(ppm): 152.9 (s, C=O), 123.8 (s, C6), 121.5 (d, C5), 81.5 (s, C1'), 80.6 (s, 
C(CH3)3), 75.9 (d, C2'), 43.4 (t, C2), 28.3 (q, 3 C, CH3 Boc), 23.6 (t, C3), 
22.5 (t, C4). MS m/z (%): 207 ([M]+, 22), 151 (65), 134 (29), 107 (81), 106 
(71), 92 (41), 79 (12), 57 (100), 41 (26). 
(3R)-6-Hex-1-ynyl-3-azido-3,4-dihydro-2H-pyridine-1-carboxylic acid 
tert-butyl ester (8f). To a solution of 8e (280 mg, 1.00 mmol) and 
triethylamine (180 μL, 1.3 mmol) in anhydrous CH2Cl2 (1.44 mL), cooled 
to –30 °C, MsCl (103 μL, 1.3 mmol) was added dropwise. After 5 min the 
cooling bath was removed and the reaction mixture was left under stirring 
for 2 h at room temperature. Then aqueous KHSO4 5% (6 mL) was 
added dropwise and, after 10 min, the mixture was extracted with CH2Cl2 
(3 x 5 mL). The combined organic layers were washed with water (3 x 10 
mL) and dried over Na2SO4. After filtration and evaporation of the solvent, 
the crude was purified by flash chromatography (n-hexane/EtOAc 4:1 + 
1% Et3N; Rf 0.20), to afford the mesylate (307 mg, 86%) as a pale yellow 
oil. 1H NMR (400 MHz) δ (ppm): 5.36 (t, J = 3.9 Hz, 1 H, 5-H), 5.01-4.98 
(m, 1 H, 3-H), 4.06 (dd, J = 13.7, 5.9 Hz, 1 H, 2-H), 3.43 (dd, J = 13.7, 
1.9 Hz, 1 H, 2-H'), 2.99 (s, 3 H, CH3 Ms), 2.56 (dm, J = 19.9 Hz, 1 H, 4-H), 
2.38 (dm, J = 19.9 Hz, 1 H, 4-H'), 2.28 (t, J = 7.0 Hz, 2 H, 3'-H), 1.52-1.43 
(m, 2 H, 4'-H), 1.46 (s, 9 H, C(CH3)3), 1.42-1.36 (m, 2 H, 5'-H), 0.87 (t, J = 
7.0 Hz, 3 H, 6'-H). The intermediate mesylate (301 mg, 0.84 mmol) was 
dissolved in anhydrous CH3CN (2 mL) and to the resulting solution 15-
crown-5 (34 μL, 0.17 mmol) and NaN3 (82 mg, 1.26 mmol) were added 
under N2 atmosphere. The mixture was heated under reflux for 6 h and 
then stirred at room temperature for 12 h. After filtration through a 
silica/celite 1:1 pad, the filtrate was concentrated under vacuum and the 
residue purified by flash chromatography (n-hexane/EtOAc, 30:1 + 1% 
Et3N; Rf 0.14), affording pure 8f (120 mg, 47%) as a pale yellow oil. [α]D
21 
= ‒ 21.0 (c 1.16, CHCl3). 
1H NMR (400 MHz) δ (ppm): 5.37 (t, J = 3.9 Hz, 
1 H, 5-H), 3.80-3.74 (m, 1 H, 3-H), 3.66-3.57 (m, 2 H, 2-H), 2.47 (ddd, J = 
19.5, 6.2, 3.9 Hz, 1 H, 4-H), 2.86 (t, J = 7 Hz, 2 H, 3'-H), 2.15 (dt, J = 19.5, 
4.7 Hz, 1 H, 4-H'), 1.53-1.44 (m, 2 H, 4'-H), 1.48 (s, 9 H, C(CH3)3), 1.43-
1.35 (m, 2 H, 5'-H), 0.88 (t, J = 7.0 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) 
δ (ppm): 153.0 (s, C=O), 122.9 (s, C6), 117.2 (d, C5), 89.2 (s, C1'), 81.4 
(s, C(CH3)3), 76.7 (s, C2'), 54.4 (d, C3), 46.3 (t, C2), 30.5 (t, C4), 29.4 (t, 
C4'), 28.1 (q, 3 C, CH3 Boc), 21.9 (t, C3'), 18.9 (t, C5'), 13.5 (q, C6'). MS 
(ESI) m/z (%): 631 ([2M + Na]+, 100), 343 ([M + K]+, 8), 327 ([M + Na]+, 
35). 
Gold-Catalyzed Rearrangement and Hydrolysis Procedure. A volume 
of the enyne solution containing 1 mmol of substrate was concentrated 
and dried under vacuum (no heating) for 30 min and then dissolved in 
anhydrous toluene (5 mL). In a two neck round bottom flask containing 
Ph3PAuCl (0.005 mmol) in anhydrous toluene (5 mL), Cu(OTf)2 (0.05 
mmol) was added under nitrogen atmosphere. After 15 min. the solution 
of enyne was added and the resulting mixture was heated under reflux 
until the starting material disappeared (TLC, usually 30 min.). After 
cooling at 85 °C (external) and dilution with tert-butyl alcohol (10 mL), 
powdered KOH (6 mmol) was added. The mixture was heated at 85 °C 
until completion (TLC, usually 15 min.) and then cooled at r.t. Water (15 
mL) was then added, and the product was extracted with EtOAc (3 x 10 
mL); the combined organic extracts were washed once with brine (15 
mL) and dried over anhydrous Na2SO4. After filtration and evaporation of 
the solvent, crude vinylogous amide (12a-e, 12g-i) was purified by flash 
chromatography to obtain the pure compound. 
(±)-1-(4-Methylpiperidin-2-ylidene)-hexan-2-one (12a). Pale yellow 
solid (133 mg, 68%). Rf 0.23 (n-hexane/EtOAc 7:1). Mp 52.6-54.1 °C. 
1H 
NMR (400 MHz) δ (ppm): 11.09 (bs, 1 H, N-H), 4.81 (s, 1 H, 1'-H), 3.39-
3.34 (m, 1 H, 6-H), 3.28-3.21 (m, 1 H, 6'-H), 2.33-2.79 (m, 1 H, 3-H'), 
2.15 (t, J = 7.4 Hz, 2 H, 3'-H), 1.98 (dd, J = 17.1, 10.5 Hz, 1 H, 3-H'), 
1.82-1.73 (m, 2 H, 4-H and 5-H'), 1.55-1.48 (m, 2 H, 4'-H), 1.40-1.24 (m, 
3 H, 5-H and 5'-H), 0.96 (d, J = 6.3 Hz, 3 H, CH3), 0.85 (t, J = 7.0 Hz, 3 H, 






6'-H). 13C NMR (100.4 MHz) δ (ppm): 197.4 (s, C2'), 163.6 (s, C2), 92.8 
(d, C1'), 41.5 (t, C6), 40.7 (t, C3), 36.7 (t, C5), 30.1 (d, C4), 28.5 (t, C3'), 
25.8 (t, C4'), 22.6 (t, C5'), 21.2 (q, CH3), 13.8 (q, C6'). MS (ESI) m/z (%): 
413 ([2M + Na]+, 100), 196 ([M + 1]+, 44). MS/MS (ESI of [M + 1]+) m/z 
(%): 178 (5), 112 (100). C12H21NO (195.30): calcd C, 73.80; H, 10.84; N, 
7.17. Found: C, 73.75; H, 10.97; N, 7.30. 
(±)-1-(6-Methylpiperidin-2-ylidene)-hexan-2-one (12b). Orange oil (111 
mg, 57%). Rf 0.13 (n-hexane/EtOAc 7:1). 
1H NMR (400 MHz) δ (ppm): 
11.06 (bs, 1 H, N-H), 4.81 (s, 1 H, 1'-H), 3.45-3.37 (m, 1 H, 6-H), 2.31-
2.26 (m, 2 H, 3-H), 2.17 (t, J = 7.5 Hz, 2 H, 3'-H), 1.91-1.84 (m, 1 H, 5-H), 
1.80-1.72 (m, 1 H, 4-H), 1.63-1.49 (m, 3 H, 4-H' and 4'-H), 1.36-1.24 (m, 
3 H, 5-H' and 5'-H), 1.20 (d, J = 6.5 Hz, 3 H, CH3), 0.86 (t, J = 7.4 Hz, 3 H, 
6'-H). 13C NMR (100.4 MHz) δ (ppm): 197.3 (s, C2'), 163.6 (s, C2), 92.5 
(d, C1'), 47.3 (d, C6), 41.5 (t, C3), 30.6 (t, C5), 28.3 (t, C4'), 28.1 (t, C3), 
22.6 (t, C5'), 22.5 (q, CH3), 18.9 (t, C4), 13.9 (q, C6').  MS (ESI) m/z (%): 
413 ([2M + Na]+, 100), 218 ([M + Na]+, 17), 196 ([M + 1]+, 65). MS/MS 
(ESI of [M + 1]+) m/z (%): 111 (100), 94 (3). C12H21NO (195.30): calcd C, 
73.80; H, 10.84; N, 7.17. Found: C, 73.61; H, 10.93; N, 7.14. 
(5S)-1-(5-Triisopropylsilanyloxypiperidin-2-ylidene)-hexan-2-one 
(12c). Yellow oil (219 mg, 62%). Rf 0.24 (n-hexane/EtOAc 10:1). [α]D
20 = 
‒ 25.4 (c 0.98, CHCl3).  
1H NMR (400 MHz) δ (ppm): 11.02 (br s, 1 H, N-
H), 4.99 (br s, 1 H, 1'-H), 4.17-4.12 (m, 1 H, 5-H), 3.48 (dd, J = 13.2, 4.0 
Hz, 1 H, 6-H), 3.21 (dd, J = 13.2, 5.8 Hz, 1 H, 6-H'), 2.64 (ddd, J = 17.5, 
7.8, 5.9 Hz, 1 H, 3-H), 2.31 (ddd, J = 17.5, 7.1, 5.9 Hz, 1 H, 3-H'), 2.21-
2.18 (m, 2 H, 3'-H), 1.91-1.84 (m, 1 H, 4-H), 1.80-1.71 (m, 1 H, 4-H'), 
1.57-1.55 (m, 2 H, 4'-H), 1.37-1.25 (m, 2 H, 5'-H), 1.10-0.96 (m, 21 H, 
TIPS), 0.88 (t, J = 7.4 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm): 
197.9 (s, C2'), 163.0 (s, C2), 93.1 (d, C1'), 64.7 (d, C5), 48.3 (t, C6), 41.6 
(t, C3), 28.4 (t, C4), 28.3 (t, C3'), 25.4 (t, C4'), 22.6 (t, C5'), 17.9 (q, 6 C, 
CH3 TIPS), 13.9 (q, C6'), 12.1 (d, 3 C, CH TIPS). MS (ESI) m/z (%): 729 
([2M + Na]+, 69), 707 ([2M + 1]+, 14), 706 ([2M]+, 33), 354 ([M + 1]+, 100). 
MS/MS (ESI of [M+ + 1]) m/z (%): 354 (4), 270 (5), 180 (100), 162 (9). 
C20H39NO2Si (353.61): calcd C, 67.93; H, 11.12; N, 3.96. Found: C, 
67.63; H, 11.21; N, 3.77. 
(5S)-1-Phenyl-2-(5-triisopropylsilanoxypiperidin-2-ylidene)ethanone 
(12d). Yellow oil (119 mg, 63%). Rf 0.10 (n-hexane/EtOAc 10:1). [α]D
24 = 
‒ 12.3 (c 1.49, CHCl3). 
1H NMR (400 MHz) δ (ppm): 11.61 (bs, 1 H, N-H), 
7.85-7.83 (m, 2 H, Ph), 7.40-7.35 (m, 3 H, Ph), 5.62 (s, 1 H, 1'-H), 4.23-
4.20 (m, 1 H, 5-H), 3.56 (dt, J = 13.3, 2.9 Hz, 1 H, 6-H), 3.30 (ddd, J = 
13.3, 5.3, 2.0 Hz, 1 H, 6-H'), 2.80 (ddd, J = 17.4, 8.0, 6.1 Hz, 1 H, 4-H), 
2.45 (dt, J = 17.4, 6.2 Hz, 1 H, 4-H'), 1.95-1.89 (m, 1 H, 3-H), 1.88-1.81 
(m, 1 H, 3-H'), 1.12-1.04 (m, 21 H, TIPS). 13C NMR (100.4 MHz) δ (ppm): 
187.2 (s, C2'), 165.0 (s, C2), 140.5 (s, Ph), 130.2 (d, Ph), 128.1 (d, 2 C, 
Ph), 126.8 (d, 2 C, Ph), 90.1 (d, C1'), 64.6 (d, C5), 48.6 (t, C6), 28.3 (t, 
C4), 25.9 (t, C3), 18.0 (q, 6 C, CH3 TIPS), 12.2 (d, 3 C, CH TIPS). MS 
(ESI) m/z (%): 769 ([2M + Na]+, 100), 746 ([2M]+, 72), 374 ([M + 1]+, 66). 
C22H35NO2Si (373.60): calcd C, 70.73; H, 9.44; N, 3.75. Found: C, 70.59; 
H, 9.72; N, 3.91. 
(5S)-1-(5-Hydroxypiperidin-2-ylidene)-hexan-2-one (12e). Yellow oil 
(128 mg, 65%). Rf 0.19 (n-hexane/EtOAc 3:1). [α]D
23 = ‒ 16.5 (c 1.34, 
CHCl3).    
1H NMR (400 MHz) δ (ppm): 10.95 (bs, 1 H, N-H), 4.89 (s, 1 H, 
1'-H), 4.29 (bs, 1 H, O-H), 4.08-4.02 (m, 1 H, 5-H), 3.44 (br d, J = 13.3 Hz, 
1 H, 6-H), 3.17 (dd, J = 13.3, 5.5 Hz, 1 H, 6-H'), 2.57 (ddd, J = 17.5, 7.4, 
5.8 Hz, 1 H, 3-H), 2.30 (dt, J = 17.5, 6.6 Hz, 1 H, 3-H'), 2.13 (t, J = 7.8 Hz, 
2 H, 3'-H), 1.89-1.83 (m, 1 H, 4-H), 1.76-1.69 (m, 1 H, 4-H'), 1.53-1.45 (m, 
2 H, 4'-H), 1.32-1.22 (m, 2 H, 5'-H), 0.85 (t, J = 7.4 Hz, 3 H, 6'-H). 13C 
NMR (100.4 MHz) δ (ppm): 197.5 (s, C2'), 163.8 (s, C2), 92.8 (d, C1'), 
63.3 (d, C5), 47.6 (t, C6), 41.5 (t, C3), 28.6 (t, C3'), 27.2 (t, C4), 25.4 (t, 
C4'), 22.5 (t, C5'), 13.8 (q, C6'). MS (ESI) m/z (%): 417 ([2M + Na]+, 100), 
220 ([M + Na]+, 14), 198 ([M + 1]+, 17). MS/MS (ESI of [M + 1]+) m/z (%): 
198 (22), 180 (100), 162 (34), 113 (58), 95 (21). C11H19NO2 (197.27): 
calcd C, 66.97; H, 9.71; N, 7.10. Found: C, 67.37; H, 10.00; N, 7.03. 
1-Azepan-2-ylidenehexan-2-one (12g). Colorless oil (142 mg, 73%). Rf 
0.25 (eluent: n-hexane/EtOAc 3:1). 1H NMR (200 MHz) δ (ppm): 11.0 (s 
br, 1 H, N-H), 4.96 (s, 1 H, 1'-H), 3.36-3.28 (m, 2 H, 7-H), 2.32-2.19 (m, 4 
H, 3-H and 3'-H), 1.68-1.28 (m, 10 H, 4-H, 5-H, 6-H, 4'-H and 5'-H), 0.90 
(t, J = 7.2 Hz, 3 H, 6'-H). 13C NMR (50.33 MHz) δ (ppm): 198.7 (s, C2'), 
169.6 (s, C2), 93.6 (d, C1'), 44.2 (t, C7), 41.9 (t, C3'), 34.9 (t, C3), 30.6 (t, 
C6), 29.5 (t, C5), 28.5 (t, C4'), 26.0 (t, C4), 22.7 (t, C5'), 14.0 (q, C6'). MS 
m/z (%): 195 ([M]+, 23), 138 (100), 111 (35). C12H21NO (195.30): calcd C, 
73.80; H, 10.84; N, 7.17. Found: C, 74.01; H, 10.90; N, 7.03. 
2-Azepan-2-ylidene-1-phenylethanone (12h). Yellow oil (140 mg, 65%). 
Rf 0.22 (eluent: n-hexane/EtOAc 3:1). 
1H NMR (200 MHz) δ (ppm): 11.54 
(br s, 1 H, N-H), 7.90-7.82 (m, 2 H, Ph), 7.42-7.35 (m, 3 H, Ph), 5.67 (s, 1 
H, 1'-H), 3.45-3.37 (m, 2 H, 7-H), 2.47-2.42 (m, 2 H, 3-H), 1.80-1.60 (m, 6 
H, 4-H, 5-H and 6-H). 13C NMR (50.33 MHz) δ (ppm): 188.1 (s, C2'), 
171.3 (s, C2), 140.6 (s, Ph), 130.3 (d, Ph), 128.0 (d, 2 C, Ph), 126.8 (d, 2 
C, Ph), 91.0 (d, C1'), 44.4 (t, C7), 35.3 (t, C3), 30.5 (t, C6), 29.3 (t, C5), 
25.8 (t, C4). MS m/z (%): 215 ([M]+, 81), 214 (100), 186 (22), 105 (24). 
C14H17NO (215.29): calcd C, 78.10; H, 7.96; N, 6.51. Found: C, 77.92; H, 
7.90; N, 6.24. 
2-Azepan-2-ylidene-1-cyclopropylethanone (12i). Colorless oil (108 
mg, 60%). Rf 0.31 (eluent: n-hexane/EtOAc 3:1). 
1H NMR (200 MHz) δ 
(ppm): 10.89 (br s, 1 H, N-H), 5.12 (s, 1 H, 1'-H), 3.34-3.26 (m, 2 H, 7-H), 
2.34-2.29 (m, 2 H, 3-H), 1.78-1.54 (m, 7 H, 4-H, 5-H, 6-H and 3'-H), 0.99-
0.90 (m, 2 H, 4'-H), 0.82-0.66 (m, 2 H, 4'-H'). 13C NMR (50.33 MHz) δ 
(ppm): 197.1 (s, C2'), 168.7 (s, C2), 93.6 (d, C1'), 44.2 (t, C7), 35.0 (t, 
C3), 30.6 (t, C6), 29.5 (t, C5), 26.0 (t, C4), 19.8 (d, C3'), 8.61 (t, 2 C, C4'). 
MS m/z (%): 179 ([M]+, 80), 138 (100). C11H17NO (179.26): calcd C, 
73.70; H, 9.56; N, 7.81. Found: C, 73.44; H, 9.82; N, 8.05. 
1-(1,4,5,6-Tetrahydropyridin-2yl)ethanone (23).[44] Pale yellow oil (22 
mg, 35%). 1H NMR (200 MHz) δ (ppm) [2:1 mixture of isomers A and B]: 
5.61 (t, J = 4.4 Hz, 1 H, 2-H, A), 4.19 (br s, 1 H, N-H, A), 3.84-3.79 (m, 2 
H, 5-H, B), 3.14 (t, J = 5.3 Hz, 2 H, 5-H, A), 2.38-2.31 (m, 2 H, 2-H, B), 
2.33 (s, 3 H, CH3, B), 2.31-2.20 (m, 2 H, 3-H, A), 2.26 (s, 3 H, CH3, A), 
1.85-1.73 (m, 2 H, 4-H, A), 1.73-1.54 (m, 4 H, 3-H, 4-H, B). 
(5R)-1-(5-Azidopiperidin-2-ylidene)-hexan-2-one (12f). A volume of the 
enyne solution containing 1 mmol of substrate was concentrated and 
dried under vacuum (no heating) for 30 min and then dissolved in 
anhydrous toluene (5 mL). A 0.2 M AgOTf solution and a 4 mM 
Ph3PAuCl solution, both in anhydrous toluene, were prepared. The 
AgOTf solution (100 μL, 0.02 mmol) was added at r.t. to the 4 mM 
Ph3PAuCl solution (5 mL, 0.02 mmol) under stirring and a nitrogen 
atmosphere, and a white precipitate immediately formed. The solution of 
enyne 8f (1.0 mmol) in anhydrous toluene (5 mL) was then added, and 
the resulting mixture was heated under reflux until the starting material 
disappeared (TLC, 30 min). The mixture was cooled at 85 °C (external) 
and diluted with tert-butyl alcohol (10 mL); powdered KOH (6 mmol) was 
added and the mixture heated at 85 °C until completion (TLC, 10 min.). 
After cooling at room temperature, water (15 mL) was then added, and 
the product extracted with EtOAc (3 × 10 mL); the combined organic 
extracts were washed once with brine (15 mL) and dried over anhydrous 
Na2SO4. After filtration and evaporation of the solvent, crude vinylogous 
amide 12f was purified by flash chromatography (n-hexane/EtOAc 3:1; Rf 
0.24) to obtain the pure compound (142 mg, 64%) as a colorless oil. 
[α]D
23 = ‒ 11.5 (c 0.92, CHCl3). 
1H NMR (400 MHz) δ (ppm): 10.99 (br s, 1 
H, N-H), 4.93 (s, 1 H, 1'-H), 3.89-3.83 (m, 1 H, 5-H), 3.49 (ddd, J = 13.3, 
4.7, 2.3 Hz, 1 H, 6-H), 3.23 (ddd, J = 13.3, 6.2, 1.9 Hz, 1 H, 6-H'),  2.55 
(ddd, J = 17.6, 7.8, 5.9 Hz, 1 H, 3-H), 2.36 (ddd, J = 17.6, 7.4, 6.3 Hz, 1 






H, 3-H'), 2.22-2.18 (m, 2 H, 3'-H), 2.03-1.95 (m, 1 H, 4-H), 1.85-1.76 (m, 
1 H, 4-H'), 1.57-1.50 (m, 2 H, 4'-H), 1.35-1.28 (m, 2 H, 5'-H), 0.88 (t, J = 
7.4 Hz, 3 H, 6'-H) ppm. 13C NMR (100.4 MHz) δ (ppm): 198.5 (s, C2'), 
161.4 (s, C2), 93.5 (d, C1'), 54.4 (d, C5), 44.5 (t, C6), 41.7 (t, C3), 28.3 (t, 
C3'), 25.4 (t, C4), 24.6 (t, C4'), 22.6 (t, C5'), 13.9 (q, C6'). MS (ESI) m/z 
(%): 467 ([2M + Na]+, 100), 245 ([M + Na]+, 38), 223 ([M + 1]+, 18). 
MS/MS (ESI of [M + 1]+) m/z (%): 166 (94), 110 (32), 93 (100), 81 (93). 
C11H18N4O (222.29): calcd C, 59.44; H, 8.16; N, 25.20. Found: C, 59.83; 
H, 7.82; N, 24.98 
 2-Hex-1-ynylpiperidine-1-carboxylic acid benzyl ester (16a). Enyne 
13a (217 mg, 0.73 mmol) was dissolved in anhydrous CH2Cl2 (36 mL) 
and NaBH3CN (275 mg, 4.37 mmol) was added; the mixture was 
vigorously stirred at r. t. for 20 min and then cooled at ‒ 50 °C. A solution 
of TFA (561 L, 7.28 mmol) in anhydrous CH2Cl2 (4.9 mL) was added 
dropwise keeping the temperature constant during the addition. The 
mixture was then allowed to warm at ‒ 20 °C and left under stirring until 
completion (TLC; 2-3 h). The reaction was then quenched by addition of 
satd NaHCO3 (40 mL) and, after separation of the phases, the product 
was extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts 
were washed once with satd NaHCO3 (40 mL) and dried over anhydrous 
Na2SO4. After filtration and evaporation of the solvent, crude 16a was 
obtained and purified by flash chromatography (eluent: n-hexane/EtOAc 
20:1; Rf 0.11) to afford pure 16a as a colourless oil (129 mg, 59%). 
1H 
NMR (400 MHz) δ (ppm): 7.36-7.28 (m, 5 H, Ph), 5.18-5.08 (m, 1 H, 2-H), 
5.14 (s, 2 H, CH2Ph), 3.98 (br d, J = 12.5 Hz, 1 H, 6-H), 3.11 (br t, J = 
12.3 Hz, 1 H, 6-H'), 2.19 (td, J = 6.8, 2.0 Hz, 2 H, 3'-H), 1.81-1.56 (m, 5 H, 
3-H, 4-H and 5-H), 1.51-1.36 (m, 5 H, 4'-H, 5'-H and 5-H'), 0.91 (t, J = 7.2 
Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ (ppm): 155.1 (s, C=O), 136.9 (s, 
Ph), 128.4 (d, 2 C, Ph), 127.9 (d, 2 C, Ph), 127.7 (d, Ph), 84.8 (s, C1'), 
77.7 (s, C2'), 67.1 (t, CH2Ph), 44.6 (t, C6), 40.5 (d, C2), 31.0 (t, C4'), 30.9 
(t, C3), 25.4 (t, C5), 21.9 (t, C5'), 19.9 (t, C4), 18.3 (t, C3'), 13.6 (q, C6'). 
MS (ESI) m/z (%): 621 ([2M+Na]+, 100), 322 ([M+Na]+, 17), 300 [M+1]+, 
4). C19H25NO2 (299.41): calcd C, 76.22; H, 8.42; N, 4.68. Found: C, 
76.33; H, 8.82; N, 4.40. 
2-Phenylethynylpiperidine-1-carboxylic acid benzyl ester (16b). 
Prepared as reported for 16a, starting from 13b (151 mg, 0.47 mmol) and 
obtaining, after purification by flash chromatography (eluent: n-
hexane/EtOAc 20:1; Rf 0.21), pure 16b (93 mg, 62%) as a pale yellow oil. 
1H NMR (400 MHz) δ (ppm): 7.43-7.29 (m, 10 H, Ph), 5.38 (br s, 1 H, 2-
H), 5.17 (s, 2 H, CH2Ph), 4.05 (br d, J = 12.3 Hz, 1 H, 6-H), 3.21 (br t, J = 
11.9 Hz, 1 H, 6-H'), 1.90-1.83 (m, 2 H, 3-H), 1.77-1.67 (m, 3 H, 5-H and 
4-H), 1.51-1.42 (m, 1 H, 5-H'). 13C NMR (100.4 MHz) δ (ppm): 155.0 (s, 
C=O), 136.7 (s, Cbz), 131.7 (d, 2 C, Ph), 128.5 (d, Ph), 128.2 (d, 2 C, Ph), 
128.1 (d, 2 C, Cbz), 127.9 (d, 2 C, Cbz), 127.7 (d, Cbz), 122.9 (s, Ph), 
84.4 (s, C1'), 77.2 (s, C2'), 67.2 (t, CH2Ph), 45.0 (t, C6), 40.7 (d, C2), 
30.8 (t, C3), 25.3 (t, C5), 20.0 (t, C4). MS (ESI) m/z (%): 661 ([2M+Na]+, 
100), 342 ([M+Na]+, 10), 320 [M+1]+, 3). C21H21NO2 (319.40): calcd C, 
78.97; H, 6.63; N, 4.39. Found: C, 78.79; H, 6.41; N, 4.84.  
2-Triethylsilanylethynylpiperidine-1-carboxylic acid benzyl ester 
(16c). Prepared as reported for 16a, starting from 13c (702 mg, 1.97 
mmol) and obtaining, after purification by flash chromatography (eluent: 
n-hexane/EtOAc 20:1; Rf 0.31), pure 16c (383 mg, 54%) as a colorless 
oil. 1H NMR (400 MHz) δ (ppm): 7.36-7.28 (m, 5 H, Ph), 5.25-5.09 (m, 1 
H, 2-H), 5.14 (s, 2 H, CH2Ph), 4.01 (br d, J = 11.3 Hz, 1 H, 6-H), 3.20-
3.05 (br m, 1 H, 6-H'), 1.90-1.74 (m, 2 H, 3-H), 1.70-1.60 (m, 3 H, 5-H 
and 4-H), 1.48-1.33 (m, 1 H, 5-H'), 0.97 (t, J = 7.8 Hz, 9 H, Si(CH2CH3)3), 
0.59 (q, J = 7.8 Hz, 6 H, Si(CH2CH3)3). 
13C NMR (100.4 MHz) δ (ppm): 
155.0 (s, C=O), 136.8 (s, Ph), 128.4 (d, 2 C, Ph), 127.9 (d, 2 C, Ph), 
127.6 (d, Ph), 104.8 (s, C2'), 86.3 (s, C1'), 67.1 (t, CH2Ph), 45.2 (t, C6), 
40.5 (d, C2), 30.7 (t, C3), 25.3 (t, C5), 19.8 (t, C4), 7.4 (q, 3 C, 
Si(CH2CH3)3), 4.4 (t, 3 C, Si(CH2CH3)3). MS (ESI) m/z (%): 737 
([2M+Na]+, 100), 380 ([M+Na]+, 10), 358 [M+1]+, 3). C21H31NO2Si 
(357.56): calcd C, 70.54; H, 8.74; N, 3.92. Found: C, 70.24; H, 8.46; N, 
4.24. 
2-Ethynylpiperidine-1-carboxylic acid benzyl ester (16d). Prepared as 
reported for 8e, starting from 16c (341 mg, 0.95 mg) and obtaining, after 
purification by flash chromatography (eluent: n-hexane/EtOAc 20:1; Rf 
0.18), pure 16d (207 mg, 89%) as a colorless oil. 1H NMR (400 MHz) δ 
(ppm): 7.39-7.29 (m, 5 H, Ph), 5.18-5.12 (m, 1 H, 2-H), 5.15 (s, 2 H, 
CH2Ph), 4.03 (br d, J = 11.7 Hz, 1 H, 6-H), 3.12 (br t, J = 12.3 Hz, 1 H, 6-
H'), 2.30 (d, J = 2.3 Hz, 1 H, 2'-H), 1.83-1.74 (m, 2 H, 3-H), 1.71-1.65 (m, 
3 H, 5-H and 4-H), 1.46-1.35 (m, 1 H, 5-H'). 13C NMR (100.4 MHz) δ 
(ppm): 155.0 (s, C=O), 136.6 (s, Ph), 128.4 (d, 2 C, Ph), 127.9 (d, 2 C, 
Ph), 127.8 (d, Ph), 81.6 (s, C1'), 72.3 (d, C2'), 67.2 (t, CH2Ph), 44.2 (t, 
C6), 40.5 (d, C2), 30.3 (t, C3), 25.1 (t, C5), 19.7 (t, C4). MS (ESI) m/z 
(%): 509 ([2M+Na]+, 100), 266 ([M+Na]+, 37), 244 [M+1]+, 7). C15H17NO2 
(243.30): calcd C, 74.05; H, 7.04; N, 5.76. Found: C, 73.79; H, 7.41; N, 
5.84. 
3-Butyl-5,6,7,8-tetrahydro-4aH-pyrido[1,2-c][1,3]oxazin-1-one (18a). 
In a two neck round bottom flask containing Ph3PAuCl (5.4 mg, 0.011 
mmol) in toluene (1.8 mL), Cu(OTf)2 (20 mg, 0.055 mmol) was added 
under nitrogen atmosphere. A solution of alkyne 16a (108 mg, 0.36 
mmol) in toluene (1.8 mL) was added and the resulting mixture was 
heated under reflux until the starting material disappeared (TLC, 1.5-2 h). 
After cooling, water (5 mL) was added and the product extracted with 
EtOAc (3 x 5 mL); the combined organic extracts were washed once with 
brine (5 mL) and dried over anhydrous Na2SO4. After filtration and 
evaporation of the solvent, crude material was purified by flash 
chromatography (eluent: n-hexane/EtOAc 5:1; Rf 0.23) to afford pure 18a 
as a colourless oil (63 mg, 83%). 1H NMR (400 MHz) δ (ppm): 4.64 (d, J 
= 2.8 Hz, 1 H, 4-H), 4.43 (dd, J = 13.2, 1.6 Hz, 1 H, 8-H), 3.78 (d, J = 
11.2 Hz, 1 H, 4a-H), 2.67 (td, J = 12.8, 2.8 Hz, 1 H, 8-H'), 2.07 (t, J = 7.6 
Hz, 2 H, 1'-H), 1.89-1.85 (m, 1 H, 7-H), 1.75-1.72 (m, 2 H, 6-H and 7-H'), 
1.58-1.41 (m, 4 H, 5-H, 6-H' and 2'-H), 1.39-1.27 (m, 3 H, 5-H' and 3'-H), 
0.89 (t, J = 7.2 Hz, 3 H, 4'-H). 13C NMR (100.4 MHz) δ (ppm): 150.2 (s, 
C1), 150.0 (s, C3), 98.6 (d, C4), 55.0 (d, C4a), 45.1 (t, C8), 34.2 (t, C5), 
32.0 (t, C1'), 28.0 (t, C2'), 25.0 (t, C7), 24.2 (t, C6), 22.0 (t, C3'), 13.7 (q, 
C4'). MS (ESI) m/z (%): 441 ([2M+Na]+, 100), 419 ([2M+1]+, 25), 210 
([M+1]+, 9). C12H19NO2 (209.28): calcd C, 68.87; H, 9.15; N, 6.69. Found: 
C, 69.05; H, 9.13; N, 6.54. 
3-Phenyl-5,6,7,8-tetrahydro-4aH-pyrido[1,2-c][1,3]oxazin-1-one 
(18b).[40] Prepared as reported for 18a, starting from 16b (90 mg, 0.28 
mmol) and obtaining, after purification by flash chromatography (eluent: 
n-hexane/EtOAc 5:1; Rf 0.19), pure 18b (48 mg, 75%) as a colorless oil. 
1H NMR (400 MHz) δ (ppm): 7.63-7.61 (m, 2 H, Ph), 7.39-7.32 (m, 3 H, 
Ph), 5.42 (d, J = 3.2 Hz, 1 H, 4-H), 4.50 (d, J = 13.6 Hz, 1 H, 8-H), 3.99 
(d, J = 10.4 Hz, 1 H, 4a-H), 2.76 (td, J = 12.5, 2.9 Hz, 1 H, 8-H'), 1.95-
1.92 (m, 1 H, 6-H), 1.83-1.80 (m, 1 H, 5-H), 1.75-1.72 (m, 1 H, 7-H), 
1.64-1.46 (m, 3 H, 5-H', 6-H' and 7-H'). 13C NMR (100.4 MHz) δ (ppm): 
149.6 (s, C1), 147.3 (s, C3), 131.8 (s, Ph), 129.2 (d, Ph), 128.4 (d, 2 C, 
Ph), 124.5 (d, 2 C, Ph), 98.7 (d, C4), 55.3 (d, C4a), 45.2 (t, C8), 33.9 (t, 
C5), 25.0 (t, C7), 24.2 (t, C6). MS (ESI) m/z (%): 481 ([2M+Na]+, 100), 
459 ([2M+1]+, 36), 230 ([M+1]+, 32). 
1-Piperidin-2-ylhexan-2-one (19a). Compound 18a (60 mg, 0.29 mmol) 
was dissolved in toluene (2.9 mL); the solution was diluted with t-butanol 
(2.9 mL) and powdered KOH (65 mg, 1.16 mmol) was then added. The 
mixture was heated at 85 °C (external) for 45 min. After cooling, water (6 
mL) was added and the product extracted with EtOAc (3 x 6 mL). The 
combined organic extracts were dried over anhydrous Na2SO4. After 
filtration, the solvent was concentrated under vacuum (caution! The 
product is volatile!) and the residue purified by flash chromatography 






(eluent: EtOAc/MeOH 1:1; Rf 0.13). The fractions were concentrated to a 
small volume under vacuum and, due to the volatility of the product, only 
a small portion was dried under vacuum for the characterization as free 
amine. Colorless oil. Rf 0.13 (EtOAc/MeOH 1:1). 
1H NMR (400 MHz) δ 
(ppm): 3.01 (d, J = 11.7 Hz, 1 H, 6-H), 2.98-2.91 (m, 1 H, 2-H), 2.66 (td, J 
= 11.7, 2.7 Hz, 1 H, 6-H'), 2.48 (d, J = 5.9 Hz, 2 H, 1'-H), 2.38 (t, J = 7.4 
Hz, 2 H, 3'-H), 2.33 (br s, 1 H, N-H), 1.78-1.72 (m, 1 H, 5-H), 1.63-1.49 
(m, 3 H, 3-H and 4'-H), 1.47-1.24 (m, 5 H, 4-H, 5-H' and 5'-H), 1.21-1.12 
(m, 1 H, 3-H'), 0.89 (t, J = 7.4 Hz, 3 H, 6'-H). 13C NMR (100.4 MHz) δ 
(ppm): 210.9 (s, C=O), 52.4 (t, C1'), 49.5 (t, C3'), 46.7 (t, C6), 43.2 (d, 
C2), 32.4 (t, C3), 25.9 (t, C4'), 25.8 (t, C5), 24.6 (t, C4), 22.3 (t, C5'), 13.8 
(q, C6'). MS (ESI) m/z (%): 184 ([M+1]+, 100). The largest portion was 
cooled in ice bath and HCl 1.25 M in MeOH (500 L) was added under 
stirring. After 30 min, the solvent was evaporated; the crude dissolved in 
a small volume of acetone and the product precipitated by adding Et2O. 
The white solid was filtered, washed with cold Et2O and dried under 
vacuum, affording pure 19a hydrochloride as a white solid (57 mg, 89%). 
19a·HCl. M.p. 115.2-116.6 °C. 1H NMR (400 MHz, D2O) δ (ppm): 3.52-
3.43 (m, 1 H, 2-H), 3.34 (dm, J = 13.2 Hz, 1 H, 6-H), 3.01-2.91 (m, 2 H, 
6-H' and 1'-H), 2.87-2.80 (m, 1 H, 1'-H'), 2.50 (t, J = 7.6 Hz, 2 H, 3'-H), 
1.87-1.77 (m, 3 H, 3-H and 5-H), 1.65-1.38 (m, 5 H, 3-H', 4-H and 4'-H), 
1.24 (sextuplet, J = 7.2 Hz, 2 H, 5'-H), 0.82 (t, J = 7.2 Hz, 3 H, 6'-H). 
C11H22ClNO (219.75): calcd C, 60.12; H, 10.09; N, 6.37. Found: C, 60.05; 
H, 9.98; N, 6.51. 
1-Phenyl-2-piperidin-2-ylethanone (19b).[10] Prepared as reported for 
19a and 19a·HCl, starting from 18b (45 mg, 0.19 mmol) and obtaining, 
after purification by flash chromatography (eluent: EtOAc/MeOH 1:1; Rf 
0.07), a small sample of free amine 19b and pure 19b·HCl (36 mg, 78%) 
as a white solid, after treatment with HCl 1.25 M in MeOH.  
19b.[10] Rf 0.05 (EtOAc/MeOH 2:1). 
1H NMR (400 MHz) δ (ppm): 7.96-
7.93 (m, 2 H, Ph), 7.59-7.54 (m, 1 H, Ph), 7.47-7.43 (m, 2 H, Ph), 3.38 
(br s, N-H), 3.24-3.04 (m, 4 H, 3-H and 6-H), 2.74 (td, J = 11.7, 2.7 Hz, 1 
H, 2-H), 1.86-1.80 (m, 1 H, 5-H), 1.73-1.62 (m, 2 H, 1'-H), 1.59-1.38 (m, 3 
H, 4-H and 5-H'). 13C NMR (100.4 MHz) δ (ppm): 199.3 (s, C=O), 136.9 
(s, Ph), 133.3 (d, Ph), 128.6 (d, 2 C, Ph), 128.1 (d, 2 C, Ph), 52.9 (t, C1'), 
46.3 (t, C6), 44.7 (d, C2), 31.9 (t, C3), 25.2 (t, C5), 24.3 (t, C4). MS (ESI) 
m/z (%): 204 ([M+1]+, 100). 
19b·HCl.[37] 1H NMR (400 MHz, D2O) δ (ppm): 7.98-7.92 (m, 2 H, Ph), 
7.70-7.63 (m, 1 H, Ph), 7.55-7.48 (m, 2 H, Ph), 3.73-3.63 (m, 1 H, 2-H), 
3.57-3.48 (m, 1 H, 1'-H), 3.44-3.33 (m, 2 H, 6-H and 1'-H'), 3.05 (td, J = 
12.4, 2.8 Hz, 1 H, 6-H'), 1.99-1.91 (m, 1 H, 5-H), 1.91-1.80 (m, 2 H, 3-H), 
1.70-1.49 (m, 3 H, 4-H and 5-H'). 
1-Methyl-5,6,7,8-tetrahydro-oxazolo[3,4-a]pyridin-3-one (21).  
Prepared as reported for 18a, starting from 16d (100 mg, 0.41 mmol) and 
obtaining, after purification by flash chromatography (eluent: n-
hexane/EtOAc 3:1; Rf 0.07), pure 21 (38 mg, 60%) as a white waxy solid. 
M.p. 45.6-46.4 °C. 1H NMR (400 MHz) δ (ppm): 3.51 (t, J = 6.0 Hz, 2 H, 
5-H), 2.43 (t, J = 6.4 Hz, 2 H, 8-H), 1.98 (s, 3 H, CH3), 1.83-1.76 (m, 2 H, 
6-H), 1.71-1.64 (m, 2 H, 7-H). 13C NMR (100.4 MHz) δ (ppm): 155.6 (s, 
C=O), 130.4 (s, C1), 117.2 (s, C9), 40.5 (t, C5), 22.4 (t, C8), 20.0 (t, C6), 
19.3 (t, C7), 9.8 (q, CH3). MS (ESI) m/z (%): 329 ([2M+Na]
+, 100), 176 
([M+Na]+, 37). C8H11NO2 (153.18): calcd C, 62.73; H, 7.24; N, 9.14. 
Found: C, 63.05; H, 6.98; N, 8.91. 
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